NeoDx Biotech Labs Introduces Real-Time PCR Diagnostic Kit for Early Detection of Ankylosing Spondylitis

HLA-B27 is a biomarker associated with inflammatory conditions such as ankylosing spondylitis, psoriasis, inflammatory bowel disease, and reactive arthritis. Early detection of these conditions is crucial for effective treatment.

Bengaluru-based healthtech startup NeoDx Biotech Labs has unveiled a real-time PCR (Polymerase Chain Reaction) diagnostic kit aimed at aiding in the early detection of ankylosing spondylitis (AS) and related inflammatory disorders. 

This HLA-B27 RT-PCR detection kit for Exon 2/Exon 3 is pivotal in identifying Human Leukocyte Antigen B27 (HLA-B27) in whole blood.

HLA-B27 is a biomarker associated with inflammatory conditions such as ankylosing spondylitis, psoriasis, inflammatory bowel disease, and reactive arthritis. Early detection of these conditions is crucial for effective treatment.

A recent study published in the Indian Journal of Rheumatology shed light on the challenges faced by individuals suffering from axial spondyloarthritis (AS). 

Shockingly, as per the study, nearly 70% of AS patients are initially misdiagnosed, often for three years or more, which worsens their condition. NeoDx's RT-PCR kit addresses this issue by providing a precise and efficient method for identifying HLA-B27, thus facilitating early treatment.

The HLA-B27 RT-PCR detection kit has undergone rigorous testing and performance assessments, demonstrating its exceptional sensitivity and specificity. Additionally, it is compatible with the majority of commercially available RT-PCR systems. 

The kit includes all the necessary reagents and controls to conduct these crucial tests effectively.

Founded in 2020 in Bengaluru, NeoDx Biotech Labs is a startup dedicated to designing, developing, and manufacturing in-vitro diagnostics (IVD) kits for diagnosing infectious diseases, cancer, and genetic disorders. 

The startup claims to provide affordable, accessible, and reliable molecular testing products to laboratories, diagnostic centers, and hospitals in India and abroad.

In a larger context, the global RT-PCR kits market is anticipated to grow substantially, targeting a consistent 6% annual increase from 2023 to 2033. 

Starting at $4 billion in 2023, this market is projected to reach $7.1 billion by 2033, fueled by the rising incidence of infectious diseases and genetic disorders. 

Healthcare providers are proactively upgrading their product offerings to meet this demand, emphasizing the development of accurate and precise testing tools. 

In May, Mylab Discovery Solutions contributed to this trend by launching the Discover Series HLAB*27 Detection Kit, an in-vitro diagnostic test designed to detect ankylosing spondylitis. This introduction further enhances the array of diagnostic solutions available in the Indian market.